We thank Wang, Jiang and Zhou [1] for their interest in our paper [2]. We agree in their conclusions that the VALUE Trial [2,3] provides critical evidence to guide antihypertensive therapy in high-risk patients. We believe, as they do [1], that continued research in this area will further improve outcomes for both patients with hypertension, renal disease or both.
